IMV Inc IMVIF

RE:RE:Presentation announced for Feb 27... new Ovarian dataset?

[alphaseeking001]

I did email the company today to see if they would acknowledge whether they are presenting any updated ovarian data but no reply as of yet.  It was late on Friday when I sent it so may not hear until next week.  They may not be in a position to divulge that either.  Fingers crossed for the 27th of Feb, but I agree with everyone on the board that common sense would seem to indicate some positive things coming.  We'll see. 

QM45 wrote:
That is a good question! I would like to know the answer to. If you can find out Alpha that would be great. Otherwise I will contact IMV. 
Ors said last year they wanted a CLEAN data set on Ovarian and were willing to wait few more months to get it to present to FDA. Hence the delay on December release. I would think this should be it. 

If you look at roster of presenters it's a great line up. 

Sally Wheatly is an expert on Survivin. She was published in a  textbook on Cancer Therapy in 2010. 
https://www.intechopen.com/books/advances-in-cancer-therapy/nuclear-survivin-cellular-consequences-and-therapeutic-implications

Jeanine Villela is a frequent Ovarian presenter at various cancer symposia. 
https://vimeo.com/241013740

Oliver Dorigo is a legend, one of the reasons I am fully invested in IMV. He presented on IMV's behalf at ASCO way back. He is a brilliant, accomplished oncologist with a great delivery. 
Should provide for nice fireworks. 

We are sitting at some interesting levels here. $5.50 is where the last round of financing was done. So although not a technical levels per say on the charts, it does provide a fair bit of resistance as all the punters in US were under water and now are made whole if they sell. Also, given the size of that financing, in some ways this is the ONLY level that matters as that's where the true volume traded. What followed barely registers in comparison. Fear vs Greed, which one will prevail? I expect this to be a short lived pause.  
If the data set on Ovarian is in line with expectations or above, we are in for a nice run.